Sample characteristics
| . | Total . | HU treated . | Not HU treated . |
|---|---|---|---|
| Patients, n (%) | 3 032 (100) | 614 (20.3) | 2 418 (79.7) |
| Sex, n (%) | |||
| Male | 1 471 (100) | 353 (24) | 1 118 (76) |
| Female | 1 561 (100) | 261 (16.7) | 1 300 (83.3) |
| Age, n (%), y | |||
| <18 | 1 746 (100) | 362 (20.7) | 1 384 (79.3) |
| 18-25 | 457 (100) | 76 (16.6) | 381 (83.4) |
| >25 | 829 (100) | 176 (21.2) | 653 (78.8) |
| Sickle genotype, n (%) | |||
| HbSS/Sβ0-thalassemia | 2 212 (100) | 542 (24.5) | 1 670 (75.5) |
| HbSC, HbSD, or HbSβ+-thalassemia | 820 (100) | 72 (8.8) | 748 (91.2) |
| Use of deferasirox, n (%) | 159 (100) | 77 (48.4) | 82 (51.6) |
| Use of blood transfusions, n (%) | |||
| Ambulatory | 417 (100) | 139 (33.3) | 278 (66.7) |
| ED | 552 (100) | 128 (23.2) | 424 (76.8) |
| Admission | 215 (100) | 56 (26) | 159 (74) |
| Total patients attending ambulatory clinic, n (%) | 2 994 (100) | 613 (20.5) | 2 381 (79.5) |
| Total patients presenting to the ED, n (%) | 1 017 (100) | 239 (23.5) | 778 (76.5) |
| Total patients admitted/hospitalized, n (%) | 381 (100) | 89 (23.4) | 292 (76.6) |
| Total costs ($) | 8 124 266.90 | 3 703 382.50 | 4 420 884.40 |
| Total costs (ambulatory) | 6 434 292.80 | 3 296 515.40 | 3 137 777.40 |
| Total costs (ED) | 550 902.50 | 128 361.80 | 422 540.70 |
| Total costs (admission) | 1 139 071.50 | 278 505.10 | 860 566.40 |
| . | Total . | HU treated . | Not HU treated . |
|---|---|---|---|
| Patients, n (%) | 3 032 (100) | 614 (20.3) | 2 418 (79.7) |
| Sex, n (%) | |||
| Male | 1 471 (100) | 353 (24) | 1 118 (76) |
| Female | 1 561 (100) | 261 (16.7) | 1 300 (83.3) |
| Age, n (%), y | |||
| <18 | 1 746 (100) | 362 (20.7) | 1 384 (79.3) |
| 18-25 | 457 (100) | 76 (16.6) | 381 (83.4) |
| >25 | 829 (100) | 176 (21.2) | 653 (78.8) |
| Sickle genotype, n (%) | |||
| HbSS/Sβ0-thalassemia | 2 212 (100) | 542 (24.5) | 1 670 (75.5) |
| HbSC, HbSD, or HbSβ+-thalassemia | 820 (100) | 72 (8.8) | 748 (91.2) |
| Use of deferasirox, n (%) | 159 (100) | 77 (48.4) | 82 (51.6) |
| Use of blood transfusions, n (%) | |||
| Ambulatory | 417 (100) | 139 (33.3) | 278 (66.7) |
| ED | 552 (100) | 128 (23.2) | 424 (76.8) |
| Admission | 215 (100) | 56 (26) | 159 (74) |
| Total patients attending ambulatory clinic, n (%) | 2 994 (100) | 613 (20.5) | 2 381 (79.5) |
| Total patients presenting to the ED, n (%) | 1 017 (100) | 239 (23.5) | 778 (76.5) |
| Total patients admitted/hospitalized, n (%) | 381 (100) | 89 (23.4) | 292 (76.6) |
| Total costs ($) | 8 124 266.90 | 3 703 382.50 | 4 420 884.40 |
| Total costs (ambulatory) | 6 434 292.80 | 3 296 515.40 | 3 137 777.40 |
| Total costs (ED) | 550 902.50 | 128 361.80 | 422 540.70 |
| Total costs (admission) | 1 139 071.50 | 278 505.10 | 860 566.40 |
HU, hydroxyurea; HbSS, homozygous sickle cell anemia; HbSC, hemoglobin SC disease; HbSD, hemoglobin SD disease.